YD Bio Business Partner EG Biomed Achieves CAP Accreditation, Advancing U.S. Clinical Testing Capabilities

Core Insights - YD Bio Limited announced that its partner EG Biomed US Inc. has received accreditation from the College of American Pathologists, enhancing its capabilities in cancer detection and diagnostics [1][2][3] Group 1: Company Achievements - EG BioMed's CAP accreditation confirms its adherence to high standards in laboratory operations, which supports YD Bio's cancer detection programs [2] - The accreditation positions YD Bio and EG BioMed to expand their diagnostic portfolio, particularly in early cancer detection and monitoring [3] Group 2: Scientific Advancements - Ruo-Kai Lin, Chief R&D Officer of EG BioMed, presented new findings on a novel circulating cell-free DNA biomarker at the AACR conference, which could monitor metastasis in advanced pancreatic cancer [4] Group 3: Company Overview - YD Bio Limited focuses on clinical trials, new drug development, cancer prevention diagnostics, and therapies for diseases with high unmet medical needs, aiming to improve patient outcomes through scientific innovation [5]